A nitroreductase with distinct properties that can activate the prodrug 5-aziridinyl-2,4-dinitrobenzamide (CB 1954) was isolated from Bacillus amyloliquefaciens. The encoding gene was identified as a homologue of the ywrO of Bacillus subtilis, and was obtained as a PCR product by reverse genetics, cloned and the entire nucleotide sequence determined. The gene was found to reside between homologues of the B. subtilis alsD and yswB genes ; however, the ywrO and yswB genes of B. amyloliquefaciens were not separated by a fourth gene, ywsA. The B. amyloliquefaciens ywrO gene was overexpressed, the recombinant protein purified and its properties were compared with those of two CB 1954-activating enzymes, Escherichia coli B nitroreductase (NTR) and Walker DT-diaphorase (DTD). In common with these enzymes menadione was an electron acceptor (K m 3 µM) and activity with this substrate was inhibited by the presence of dicoumarol (K i 10 µM). 
INTRODUCTION
The monofunctional prodrug 5-aziridinyl-2,4-dinitrobenzamide (CB 1954) can be activated to form a cytotoxic hydroxylamine derivative by nitroreductase enzymes ( Fig. 1) (Anlezark et al., 1995 ; Knox et al., 1988b) . The difunctional alkylating agent formed upon reduction with these enzymes can cross-link DNA via a non-enzymic combination with cellular thiols . Therefore, CB 1954 has potential applications in cancer therapy. CB 1954 is toxic to Walker rat carcinoma cells due to the presence of a form of NAD(P)H oxidoreductase, DT-diaphorase (DTD ; EC 1;6;99;2) (Knox et al., 1988b) , in these cells. The enzyme DTD was originally defined as having the ability to use the cofactors di-and triphosphopyridine nucleotide (NADH and NADPH) equally well. Although other mammalian cells, including human cells, do not possess an equivalent DTD activity (Boland et al., 1991 ) the conversion of CB 1954 to hydroxylamine can be exploited in cancer therapy using directed enzyme prodrug therapy (DEPT) approaches.
DEPT involves directing an exogenous enzyme with the required properties to the target tumour as a fusion protein, as part of an antibody-enzyme conjugate (antibody-directed enzyme prodrug therapy, ADEPT) (Bagshawe, 1987 ; Bagshawe et al., 1988) , or by delivering the encoding gene to the target cells. The presence of the functional enzyme will eliminate the targeted cells and, through a bystander effect, will also eliminate cells in the immediate vicinity of the targeted cells on administration of the prodrug (gene-\viral-directed enzyme prodrug therapy, GDEPT\VDEPT, or clostridial-directed enzyme prodrug therapy, CDEPT) (Dachs et al., 1997 ; Minton et al., 1995 ; Lemmon et al., 1997) .
Bacterial enzymes offer a number of advantages in DEPT strategies in that there is often no mammalian equivalent and their substrate specificity may differ substantially from that of mammalian enzymes so that non-specific prodrug activation, at sites other than the tumour, can be avoided. A ' classical ' nitroreductase (NTR) isolated from Escherichia coli B activates CB 1954, and its bischloroethyl analogues and orthologues, to form cytotoxic derivatives (Anlezark et al., , 1995 . The use of NTR in ADEPT is, however, limited by the requirement for a cofactor to be co-administered with the prodrug and by the achievable level of enzyme activity in the tumour when directed there by chemical conjugation with antibody fragments (Anlezark et al., 1996 ; G. M. Anlezark, unpublished data) . However, NTR has been used in gene therapy approaches with some success in vitro (Bailey et al., 1996 ; Bridgewater et al., 1997 ; Searle et al., 1998 ; Latham et al., 2000) and in animal models (Clark et al., 1997 ; Drabek et al., 1997 ; McNeish et al., 1998) . Nevertheless, in common with Walker DTD, the kinetics of the enzyme-substrate interaction are suboptimal . Furthermore, in contrast to the single cytotoxic product formed by the Walker enzyme, the reaction catalysed by Fig. 1 . Structure of CB 1954 and the E. coli B reduction products formed. The cytotoxic 4HX product is converted intracellularly into a DNA cross-linking agent by a non-enzymic mechanism .
NTR results in the formation of two products, the 4-hydroxylamine (4HX) and the relatively non-toxic 2-hydroxylamine (2HX) derivatives ( Fig. 1 ; Knox et al., 1992 ; Anlezark et al., 1992) . This limits the use of NTR in gene therapy, where the efficiency of transfection and the expression of proteins from transfected genes can be low, particularly in vivo.
Ideally, a DEPT enzyme should fulfill a number of criteria for its successful use including a high affinity and specificity for the substrate, and a high turnover so that sufficient cytotoxin is generated within the tumour for clinical efficacy even if transfection and expression efficiency is low. We have previously screened a number of bacterial classes for prodrug-activating activity and these studies have indicated that an enzyme with the desired properties is present in some Bacillus spp. (G. M. Anlezark, unpublished data). The present study describes the isolation of a novel nitroreductase from Bacillus amyloliquefaciens, and its purification, characterization and evaluation as a candidate for DEPT strategies.
METHODS
Bacterial strains, plasmids and culture media. The source of chromosomal DNA for the cloning of ywrO was B. amyloliquefaciens (CAMR strain 0454). The E. coli host used for cloning experiments was Top10 [F − mcrA ∆(mrr-hsdRMSmcrBC) φ80lacZ∆M15 ∆lacX74 recA1 deoR araD139 ∆(araleu)7697 galU galK rpsL (Str R ) endA1 nupG], and the host used for expression studies was E. coli novablue [endA1
thi-1 recA1 gyrA96 relA1 lac (Fh proA + B + lacI q lacZ∆M15 : : Tn10)]. Plasmids employed for cloning and expression studies, respectively, were pCR2.1-TOPO (Invitrogen) and pET21b (Novagen). All organisms were cultivated in L-broth or on L-agar at 37 mC and supplemented where necessary with antibiotics (100 µg ampicillin ml − " or 30 µg kanamycin ml − "). For enzyme purification and DNA preparation, 20 ml L-broth was inoculated with a single colony of B. amyloliquefaciens and grown at 37 mC with gentle shaking for 6-8 h. A 1 ml aliquot of the starter culture was thereafter used to inoculate 200 ml L-broth in a 1 l unbaffled flask which was then incubated overnight at 37 mC with shaking at 150 r.p.m. Cells YwrO : cloning, expression and CB 1954 activation were harvested by centrifugation and washed with 20 mM potassium phosphate buffer, pH 7n0, before use, or stored at k20 mC until required.
All chemicals and reagents used throughout this study were purchased from Sigma unless otherwise indicated.
General recombinant methods. The pCR2.1-TOPO cloning vector was used in accordance with the manufacturer's (Invitrogen) instructions. All recombinant methods including isolation of plasmid DNA, cultivation and transformation of E. coli, and all molecular manipulations of DNA were performed as described by Sambrook et al. (1989) . All restriction endonuclease and DNA-modifying enzymes were used in accordance with the supplier's instructions (NBL). For nucleotide sequencing 1-2 µg template DNA was mixed with 4n5 pmol oligonucleotide primer and the sequencing reaction was completed using AmpliTaq FS dye terminator chemistry in a robotic workstation. DNA sequence analysis was performed using an ABI Prism DNA sequencer (Perkin Elmer). Native Pfu DNA polymerase was obtained from Stratagene. Oligonucleotides were synthesized on an ABI synthesizer (Perkin Elmer). Primary data were manipulated using software in the Lasergene program (DNA STAR). Inverse PCR was performed as described by Whelan et al. (1992) .
Cloning of the ywrO gene. A 230 bp portion of ywrO was amplified from the B. amyloliquefaciens chromosome using the two degenerate primers P1 (5h-GTNCAYCCNGATAT-GGARAA-3h) and P2 (5h-CCRTANGCCCANCCRTG-3h); P1 was capable of encoding an heptapeptide motif from the determined N-terminal sequence of the purified enzyme (VHPDMEN) and P2 could encode an internal sequence motif (HGWAYG) found to be entirely conserved between the hypothetical bacterial proteins YrkL (Bacillus subtilis) and YabF (E. coli). The 230 bp fragment was cloned into pCR2.1-TOPO to yield pBAM1 (Fig. 2) . The remainder of the gene was isolated by using inverse PCR. B. amyloliquefaciens chromosomal DNA was cleaved with StyI, and the fragments generated were circularized through their subsequent incubation with DNA ligase. The ligated DNA was then used as the template for a PCR employing two divergent primers based on the sequenced 230 bp fragment : primers P3 (5h-GCTTATTGACCGCTGAG-3h) and P4 (5h-GTACAGTGC-GCCTCCGC-3h). A 2n9 kb fragment was generated and cloned into pCR2.1-TOPO (Invitrogen), and the sequence of the insert of the recombinant plasmid pBAM2 was determined. This allowed the identification of the nucleotide sequence of the remaining parts of the B. amyloliquefaciens gene. Using this information, a contiguous copy of the entire structural gene was amplified from the B. amyloliquefaciens chromosome using primer P5 (5h-GGTGTGATACATATGAAAG-TATTG-3h), which encompassed the translational start codon, and a primer residing 3h to the translational stop codon (P6, 5h-CGGGGATTCGAATTCTTTCTCAGG-3h). The contig was then inserted into pCR2.1-TOPO to give pBAM3. The primer at the 5h-end of the gene (P3) was designed such that the sequence immediately 5h to the ATG start codon became CAT. This change created a NdeI site (CATATG), thereby allowing the gene to be cloned into the equivalent site of the expression vector pET21b to yield pBAM4. The primer at the 3h-end of the gene (P4) contained a recognition site for EcoRI.
Enzyme analysis. Quantitative enzyme assays using CB 1954 or bischloroethyl-2,4-dinitrobenzamide (SN 23862) (generous gifts from Dr D. Wilman, Institute of Cancer Research, Sutton, Surrey, UK, and Professor W. Denny, University of Auckland, New Zealand, respectively) as substrate were carried out at 37 mC by HPLC as previously described (Anlezark et al., , 1995 . In this system peaks for substrate, cofactor and reduction products are baseline-separated with the following retention times : NAD(P)H 1n1 min, 4HX 2n1 min, 2HX 2n6 min and CB 1954 3n3 min. Reaction components were quantitated by comparison of peak areas with those of standards run on the same column. A typical peak area for 1 mM CB 1954 would be calculated at 6-7i10' milli absorbance units and peaks of 5 % of this area are readily detected. When qualitative assays were used to identify column fractions the standard conditions were as follows : 1 mM prodrug, 2 mM NAD(P)H, 4 % (v\v) DMSO (Aldrich, reagent grade) in 100 mM sodium phosphate buffer, pH 7, at 37 mC. The presence of nitroreductase activity was indicated by a colour change in the reaction mixture from pale yellow to a deep golden yellow for CB 1954, or from bright yellow to brown for SN 23862. Assays using menadione as the substrate were carried out spectrophotometrically as described by Knox et al. (1988a) using cytochrome c as the terminal electron acceptor. Similar procedures were used to assay flavin reductase activity with FMN and FAD as the substrates. Cofactor concentrations in these assays were at least 500 µM to ensure saturation. Protein concentrations were estimated by BCA assay (Pierce). All spectrophotometric analyses were carried out using a Lambda 2 spectrophotometer (Perkin Elmer).
Kinetic parameters were calculated using Enzfitter (Biosoft), a non-linear regression data analysis program. Results are expressed as K m or V max p. Each calculation is based on a minimum of at least ten reaction rate determinations.
Purification of native B. amyloliquefaciens YwrO. A 54 ml crude extract was prepared by sonication from a 2n4 l overnight L-broth culture of strain 0454, after resuspending the washed cell pellet (23 g) in 20 mM potassium phosphate buffer, pH 7n0. DNAase and RNAase were added before centrifugation to aid clarification of the extract. Ammonium sulphate precipitation was performed as follows. The extract was brought to 60 % saturation by addition of 19n5 g solid ammonium sulphate and centrifuged (15 000 r.p.m., 15 min) to remove the precipitate. The supernatant (57 ml) was then brought to 90 % saturation by addition of a further 11n5 g solid ammonium sulphate and centrifuged again. The resulting pellet containing the majority of the nitroreductase activity was resuspended in 5 ml 20 mM Tris pH 7n6, desalted using a PD10 column of Sephadex G25 (Pharmacia) and analysed by chromatography using FPLC Mono Q equilibrated in the same buffer. After washing off unbound proteins, elution was by gradient to 0n3 M KCl. Fractions active with CB 1954 eluting between 120 and 150 mM KCl were pooled, concentrated and desalted before reapplying to Mono Q equilibrated in 20 mM Bistris, pH 6. Elution was again by KCl gradient, and the active fractions eluted at 120-140 mM KCl were pooled and concentrated.
Electrophoresis. Homogeneity of the purified protein was assessed in SDS-or native-PAGE in 8-25 % gradient Phastgels using a Phastsystem (Amersham), or in 4-12 % gradient NuPage Bistris gels (Novex) according to the manufacturers' instructions. Visualization of the protein bands was by Coomassie staining (Phastsystem) or silver staining (Bio-Rad) according to the protein concentration. For final identification of the active protein in IEF or the native-PAGE gels, 4-6n5 IEF Phastgels or Novex 4-20 % gradient Tris\glycine gels were used. Activity staining was performed using o-methyl red (200 µM in 20 mM Bistris, pH 7n0, 1 % DMSO) and NAD(P)H (500 µM) as a cofactor. The gels were placed in lidded Petri dishes and flooded with 0n5-1n0 ml NAD(P)H, followed by 1-2 ml o-methyl red solution and left at 37 mC for approximately 30 min. After this time the dye had penetrated the gel and a zone where the dye had been decolourized by the action of the enzyme was clearly visible. Images were captured in an ImageMaster imaging system (Amersham) using a blue filter to enhance contrast.
In vitro cytotoxicity assays. Microtitre plates (96-well) were pre-seeded with V79 cells (European Collection of Animal Cell Cultures) at 10 000 cells ml − " in Dulbecco's modified Eagle's medium (DMEM ; Sigma) plus 10 % (v\v) fetal calf serum. All treatments were prepared on duplicate plates and transferred to the cells prior to adding enzyme (10 µl) to the appropriate wells. CB 1954 was dissolved in DMSO (Sigma, tissue culture grade) so that the appropriate concentrations could be dispensed by adding 5 µl of the solution to each well. NAD(P)H was dissolved in sterile PBS to give the appropriate final concentration by adding 10 µl of the solution to each well. Enzymes were diluted in sterile PBS. All aqueous solutions were filter-sterilized before use and all operations were carried out in a laminar-flow hood. The cells were exposed for 3 h to CB 1954 (3n9-500 µM in doubling dilutions) alone, or in combination with cofactor (NAD(P)H 125 or 250 µM) and enzyme (4 µg), by removing the growth medium and replacing it, after washing twice with PBS, with 200 µl serum-free medium containing the various reaction components. After exposure, the cells were washed with PBS, fresh medium containing serum was added and the plates were left to incubate at 37 mC, 5 % CO # for 4 d. At this time cells in control (untreated) wells had achieved confluent growth. Cytotoxicity was quantified by the sulphorhodamine B assay (Rubinstein et al., 1990) . Briefly, the growth medium was removed and the cells were fixed by addition of cold trichloroacetic acid (TCA) (10 %, w\v ; 100 µl per well) for 30 min. The TCA was removed and the fixed cells were washed with water before the addition of 0n4 % SRB in 1 % (v\v) acetic acid (100 µl per well) and incubation at room temperature for 30 min. Excess dye was removed and the wells were washed four times with 1 % (v\v) acetic acid. After air drying at room temperature the dye was solubilized by adding 100 µl 10 mM Tris to each well and shaking for 15 min. The plates were read at 492 nm in a Titertek plate reader. Cytotoxicity towards treated cells was expressed as a percentage of the A %*# value for the control wells.
RESULTS

Purification of a nitroreductase from B. amyloliquefaciens strain 0454
Following the procedures outlined in Methods, SDS-PAGE on an 8-25 % gradient Phastgel indicated the presence of one major band and several minor bands in the concentrate. To confirm that the major band was the nitroreductase, the concentrate was applied to an IEF gel and, after focusing, the gel was sliced to allow Coomassie blue staining of one half and an activity stain (omethyl red, which is decolourized by the enzyme) to be applied to the other half. A clear band of decolourized dye corresponding to the position of the major Coomassie-stained band appeared on incubation of the gel with the dye and NADPH. Throughout the purification, qualitative CB 1954 assays only could be carried out since the endogenous enzyme was present at very low levels. (Kunst et al., 1997) . Some similarity was also noted with two hypothetical E. coli proteins, YabF and YheR (28 and 33 % identity, respectively). In view of this observation, a strategy was formulated whereby sequence homology between the identified bacterial proteins, together with the determined N-terminal amino acid sequence of the discovered B. amyloliquefaciens enzyme, was used to amplify a region of the desired encoding gene from the B. amyloliquefaciens genome (see Methods). Nucleotide sequencing of the insert of the plasmid obtained (pBAM1) revealed the presence of an ORF which encoded a polypeptide that shared 66 % sequence similarity with YrkL. To obtain the 5h-and 3h-ends of the gene, inverse PCR was used to clone a 2n9 kb StyI fragment. The insert of the plasmid obtained (pBAM2) was partially sequenced, allowing the subsequent isolation, by PCR, of the entire structural gene as an approximately 550 bp fragment and its insertion into either pCR2.1-TOPO (pBAM3) or pET21b (pBAM4).
Comparative analysis of the predicted amino acid sequence of the cloned gene indicated that it shared a high degree of similarity to the hypothetical B. subtilis protein YrkL (50 % identity). However, a higher degree of similarity (69n7 % identity) was evident to a hypothetical protein, YwrO, of a subsequently determined B. subtilis gene. In view of this higher degree of homology, the cloned B. amyloliquefaciens gene was designated ywrO and its encoded protein was designated YwrO. In B. subtilis, the ywrO gene is preceded by a gene (alsD) encoding acetolactate decarboxylase and followed by two hypothetical genes encoding proteins YwsA and YwsB, both of which have unknown function(s). This arrangement of genes is largely conserved in B. amyloliquefaciens (Fig. 2) . Thus, an ORF encoding a protein which shares 90n2 % identity with the B. subtilis AlsD protein resides at the 5h-end of the B. amyloliquefaciens ywrO gene, while the incomplete ORF found downstream encodes a protein which exhibits 48n6 % identity with YswB. One obvious difference between the two bacilli, however, is the fact that in B. subtilis a further small gene, yswA, resides between the ywrO and yswB. The equivalent gene does not appear in this position in the B. amyloliquefaciens genome (Fig. 2) .
Purification and characterization of recombinant B. amyloliquefaciens YwrO
To facilitate subsequent expression studies, a NdeI site was created over the translational start codon of the gene during its amplification by PCR. This NdeI site, Only an internal 1n5 kb fragment (indicated by \\ and BB in the map) of the 2n9 kb StyI fragment was sequenced. The region of the ywrO gene originally amplified (cloned into pCR2.1 to generate pBAM1), using the primers P1 and P2, has been shaded black. The position of the primers P3 and P4 used to generate the inverse PCR fragment cloned in pBAM2 is also shown beneath the shaded region of ywrO. Plasmids pBAM3 and pBAM4 were made by inserting a DNA fragment generated by PCR using the primers P5 and P6 into pCR2.1-TOPO and pET21b between the vector NdeI and EcoRI sites (see Methods). A prime (h) before or after the gene indicates either a 5h-or 3h-truncation, respectively. Also marked are the following vector-borne elements : lac, the lacZ promoter ; T 7 , the T 7 polymerase promoter ; ori, the ColE1 origin of replication ; Km R , the kanamycin resistance gene ; Ap R , the ampicillin resistance gene.
together with an EcoRI site created at the 3h-end of the gene, was used to subclone ywrO into the equivalent sites of the expression vector pET21b. This placed the translational start codon of ywrO in the resultant plasmid, pBAM4, at the optimal distance from the vector-encoded ribosome binding site. E. coli novablue cells carrying pBAM4 were grown overnight at 37 mC following induction with IPTG. A crude extract was prepared in 20 mM potassium phosphate buffer, pH 7, by sonication with the addition of DNAase and RNAase before centrifugation to aid clarification. Purification was essentially as described above for the native enzyme, omitting the initial ammonium sulphate fractionation step. The supernatant was buffer-exchanged into 20 mM Tris, pH 7n6, for separation on FPLC Mono Q. A second anion-exchange step was performed in 20 mM Bistris, pH 6, and following this the protein appeared essentially homogeneous on SDS-PAGE (not reduced) (Fig. 3b) . The yield from the small-scale process was approximately 25 % with a 24-fold increase in specific activity (Table 1 ). The pure protein was also electrophoresed on native NuPage 4-12 % gradient gels and activity-stained not show true mobility in native-PAGE and so are not annotated. Lanes 1-7 were stained with Coomassie blue ; lanes 8-14 were activity-stained with o-methyl red as described in Methods. Lanes : 1, markers (SeeBlue Plus 2) ; 2, blank ; 3, crude extract as in Fig. 3(b) ; 4, partially purified YwrO ; 5, blank ; 6, purified YwrO ; 7 and 8, blank ; 9, purified YwrO ; 10, partially purified YwrO ; 11, blank ; 12, crude extract ; 13, blank ; 14, molecular mass markers. using NAD(P)H and o-methyl red. Decolourized bands were clearly seen in lanes containing the YwrO protein (Fig. 3b) .
The estimated molecular mass from comparison with low-molecular-mass standards was 21n5 kDa, which agrees well with the value calculated from the deduced amino acid sequence. By gel filtration (Superdex 75), however, the molecular mass was estimated to be approximately 88 kDa, suggesting that the protein exists as a tetramer in the native state. The spectrum of the pure protein was typical of a flavoprotein with λ max at 381 and 451 nm (Fig. 3a) .
Kinetic parameters with respect to CB 1954 were determined by HPLC assay using 10 µl of the final product in a 500 µl assay mix containing 100-1000 µM CB 1954, 500 µM NADPH and incubating the mixture at 37 mC for 10 min. Reduction of CB 1954 was determined by comparison of peak areas at 325 nm in standard and enzyme tubes. K m was calculated to be 618p169 µM with a V max of 5n5 µmol min −" mg −" , giving a k cat of 8n2 s −" . The single product formed was found to be exclusively the cytotoxic 4HX derivative. As described in Methods, reduction product peaks were baseline-separated from each other and from those of values for the control cells, meanpSD (untreated, A 492 1n6p0n05, n l 24). Each point represents the mean (pstandard deviation, n l 6) of at least six wells in two independent experiments. All treatments were carried out in serum-free DMEM. For wells exposed to prodrug, cofactor and enzyme, five concentrations of CB 1954 in doubling dilutions from 500 µM (B. amyloliquefaciens YwrO) or 50 µM (NTR) were used. Statistical analysis was performed using the Mann-Whitney test comparing the median values for prodrugjcofactor with those for prodrugjcofactorjenzyme at each dose of prodrug. The asterisks denote significant differences between the medians, P 0n05. the cofactor and substrate, and very small peaks could be detected. The only peaks detected in any sample were for CB 1954, NADPH and the 4HX product. There was no activity with the bischloroethyl analogue of CB 1954, SN 23862, with either NADPH or NADH as the cofactor.
B. amyloliquefaciens YwrO could use FMN and FAD as substrates and acted as a menadione reductase (Table 2) . With all of these substrates the rate of reaction was 2-10-fold faster with NADPH than with NADH (data shown for FMN and NAD(P)H only). When menadione was used as the substrate the rate of reaction with NADH as cofactor was very low ( 5 µmol min −" ml −" with 10 µM menadione against 40 µmol min −" ml −" with NADPH as cofactor) and kinetic parameters with this cofactor were not determined. The cofactor concentration in all cases was at least 500 µM to ensure saturation. Substrate inhibition was seen with concentrations of menadione greater than 10 µM and therefore the kinetic parameters were determined using the Cornish-Bowden method (Cornish-Bowden, 1979) (Fig. 4) .
In vitro cytotoxicity tests
The sulphorhodamine B assay was used to determine the cytotoxicity of the combination of enzyme, cofactor and CB 1954 on V79 cells of NTR and B. amyloliquefaciens YwrO. Exposure of the cells for 3 h to the various treatments was carried out in serum-free medium to avoid activation of CB 1954 by endogenous enzymes. The results are shown in Fig. 5 . Control curves are shown for prodrug alone or in combination with either NADH or NADPH. Other controls were performed concurrently in each experiment (enzyme alone or with prodrug or cofactor, cofactor alone or with prodrug, DMSO alone) but none of the median absorbance values differed significantly from those of untreated cells (P 0n05, Mann-Whitney test).
Under the conditions used CB 1954 (3n9-500 µM) was not cytotoxic either alone or in combination with NADH or NADPH. However, in the presence of 4 µg B. amyloliquefaciens YwrO or NTR there was a doserelated cytotoxic effect. The ED &! values for the two enzymes were calculated by probit analysis and were 6n3p0n5 µM (NTR) (95 % confidence intervals 5n4-7n3) and 137n1p8n2 µM (B. amyloliquefaciens YwrO) (95 % confidence intervals 121n9-154n4).
DISCUSSION
The aim of this study was to isolate and characterize a novel enzyme for DEPT strategies. For nitroreductases the strategies of choice are likely to be of the GDEPT or VDEPT type because of the necessity and inherent difficulty of providing exogenous cofactor for ADEPT approaches (Knox et al., 1995 ; Anlezark et al., 1996) . Whilst the requirements for prodrugs for the alternative approaches may be different (Connors, 1995 ; Denny & Wilson, 1998) , the requisite properties of the enzymes are probably substantially alike in that selectivity, a high affinity for the substrate and a high turnover are the principal considerations. Additionally, if CB 1954 is to be used as a prodrug, consideration needs to be given to product formation. The E. coli B NTR reduces CB 1954 to produce a mixture of the two hydroxylamine reduction products (Fig. 1) , one of which (the 2HX) is substantially less cytotoxic. Therefore, it is considered an advantage for a DEPT enzyme to produce the 4HX derivative only and certainly not solely the 2HX. Alternative prodrugs also merit attention, including analogues of CB 1954 (Palmer et al., 1992 Anlezark et al., 1995) and other compounds where nitroreduction is a ' trigger ' for activation (Mauger et al., 1994 ; Siim et al., 1997) . An individual enzyme might not possess all the desired properties or substrate specificity, but if a portfolio of enzymes could be identified with specificity for one or more classes of prodrugs, exploitation of nitroreduction for prodrug activation in cancer therapy (Connors, 1995) could find applications in a wide spectrum of disease.
The B. amyloliquefaciens YwrO protein described in the present study possesses at least two of the desired attributes for DEPT. Firstly, it produces only 4HX from the reduction of CB 1954 and secondly, it has a higher affinity for the prodrug than either NTR or Walker DTD (K m values of 617, 862 and 826 µM, respectively), with its k cat being comparable to that of NTR (and greater than that of Walker DTD). However it cannot use the mustard analogue of CB 1954 as a substrate. As yet few enzymes with optimal properties have been available, with the only published alternatives to NTR being the Walker rat carcinoma DTD and human NQ02 (Knox et al., 1988a ; Wu et al., 1997) .
As well as being able to reduce CB 1954, B. amyloliquefaciens YwrO has a number of other properties in common with DTD or NTR. It is a flavin reductase and can use either FAD or FMN as substrates, although the affinity for the latter is greater. NTR has flavin reductase activity, but the flavins are relatively poor substrates and reduction rates are low (G. M. Anlezark, unpublished data), as they are for a highly related protein NfsB, compared with proteins from other related species (Zenno et al., 1996) . B. amyloliquefaciens YwrO is also an azoreductase, rapidly reducing the azodye o-methyl red.
The B. amyloliquefaciens protein described in this work has been identified with the aid of the complete genome sequence of a highly related organism. The value of sequence homology in these circumstances for identifying and screening enzymes for specific properties, such as prodrug activation, is clear. In the present work we have cloned and overexpressed the previously unknown product of a gene which was identified by sequence homology to be an orthologue of the ywrO of B. subtilis. In Bacillus spp., and amongst members of other genera (Bryant et al., 1981 ; Kinouchi & Ohnishi, 1983 ; Rosenkranz et al., 1982 ; G. M. Anlezark, unpublished data) , total nitroreductase activity assayed in crude cell extracts often represents activity of at least three enzymes which can be purified individually only with difficulty (G. M. Anlezark, unpublished data). In the course of this study we have also cloned and overexpressed the B. subtilis gene (G. M. Anlezark, unpublished results), but the protein had relatively little activity with the prodrugs CB 1954 or SN 23862. This demonstrates that sequence homology may not always indicate structural homology or similar enzymesubstrate interactions. Nevertheless, searching genomes and databases for homologous sequences offers a relatively rapid screening method for identification of potentially useful enzymes for DEPT strategies. Using the entire genome sequence of B. subtilis and database mining, we have already identified further genes potentially encoding prodrug-reducing enzymes which will form the basis of further publications.
B. amyloliquefaciens YwrO shows no sequence homology with NfnB or other Enterobacteriaceae nitroreductases, but shares a degree of homology with Walker DTD, other mammalian diaphorases and NQ02. Sequence differences may contribute to the greater ability of the bacterial enzyme and NQ02 to turn over CB 1954 compared to other DTDs. In particular, the Walker enzyme and NQ02 (active with CB 1954) have a Tyr residue at position 104, whereas NQ01 (DTD) and the mouse enzymes (low CB 1954 activity) do not. This residue has been shown to have a significant effect on the affinity of the proteins for CB 1954, with the substitution of Tyr for Gln shifting the properties of NQ01 and mouse enzymes towards those of the Walker enzyme and NQ02 (Chen et al., 1997) with respect to CB 1954. B. amyloliquefaciens and B. subtilis YwrO share the Tyr in the equivalent position in their sequences, but these differences may not represent all of the critical residues involved in prodrug reduction because B. subtilis YwrO has very low activity with CB 1954, reducing the prodrug too slowly to be of clinical use, despite its high degree of homology with B. amyloliquefaciens YwrO. Further studies will be necessary to elucidate which parts of the molecules are essential for efficient production of the 4HX cytotoxin. Although YwrO produces only the cytotoxic 4HX derivative of CB 1954, in contrast to the 2HX and 4HX products of the prodrug reduction by NTR, its effects in cytotoxicity assays are less than those of NTR under the same conditions. It is difficult to say how an in vitro experiment will relate to an in vivo situation where the gene product is being expressed in mammalian cells. The k cat value of the novel protein is lower than that of the NTR and it is not yet known which of the kinetic parameters will prove to be crucial in an in vivo setting. Nevertheless, the k cat value of B. amyloliquefaciens YwrO is greater than that of the Walker enzyme, which is able to achieve efficient in vitro cytotoxicity using CB 1954 and NADH (Knox et al., 1988b) . It may be that a critical concentration of the toxic product is needed in vitro, where a relatively low initial cell density will allow diffusion of the product away into the surrounding medium. In a dense tumour mass diffusion will be restricted and an enzyme working relatively slowly will not be a disadvantage. Three-dimensional tumour models may provide a better estimate of in vivo efficacy (Hoffman, 1993 ; Santini & Rainaldi, 1999) and it remains to be seen which enzyme will be effective when expressed in in vivo models.
